Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA Transparency Initiative Overview

FDA Transparency Initiative Overview Home
          About FDA
          Transparency
          FDA Transparency Initiative Overview
          Fact Sheet: FDA Good Guidance PracticesFDA Transparency Initiative Overview Fact Sheet: FDA Good Guidance Practices
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFDA guidances are documents that explain the agency’s interpretation of, or policy on, a regulatory issue. The FDA prepares guidances primarily for industry, but also for other stakeholders and its own staff, and uses them to address such matters as the design, manufacturing, and testing of regulated products; scientific issues; content and evaluation of applications for product approvals; and inspection and enforcement policies.Although guidances are not legally binding, they show stakeholders one way to reach their regulatory goal. However, stakeholders are free to use other approaches that satisfy the relevant law and regulations. Recently, FDA published a report on how to improve the processes that make these important documents available.**Guidance Development**FDA issues more than 100 guidances each year. In fiscal year (FY) 2009, for example, FDA issued approximately 124 draft and final guidance documents; in FY 2010, the total was approximately 133, and in FY 2011, it was approximately 144. FDA develops two types of guidance documents - Level 1 and Level 2.  In general:Level 1 guidances set forth the agency’s initial interpretations of new significant regulatory requirements; describe substantial changes in FDA’s earlier interpretation or policy; and deal with complex scientific or highly controversial issues.Level 2 guidances usually address existing practices or minor changes in FDA’s interpretation or policy.Industry, consumers and other stakeholders play a significant role in the agency’s guidance development processes.  FDA welcomes individuals’ and stakeholders’ suggestions of topics for guidances, and in certain instances solicits draft proposals.  Draft proposals can help the agency better understand stakeholder positions, particularly if the subject involved deals with novel scientific issues.The agency also invites the public to comment on its draft Level 1 guidances and reviews and considers the submitted comments in preparing the final documents. In some instances, FDA may hold public meetings or workshops on draft Level 1 guidance to solicit additional comments, or it may present draft Level 1 guidance to an advisory committee for review.Although Level 2 guidances and Level 1 guidances “for immediate implementation” are implemented without prior public comment, all FDA guidances are posted on the agency’s Web, and anyone can submit comments on any guidances after they are implemented.  FDA reviews those comments and revises the guidances, if necessary.**A Blueprint for Improvement**As part of the Transparency Initiative, Dr. Margaret A. Hamburg, the Commissioner of Food and Drugs, called for a cross-Agency working group to prepare a report identifying FDA’s “best practices” for making the agency’s guidance development processes more transparent and efficient.The working group, under the leadership of the Office of Policy in the Office of the Commissioner, prepared a report, entitled the Food and Drug Administration Report on Good Guidance Practices:  Improving Efficiency and Transparency (GGP Report).Download the Fact Sheet: FDA Good Guidance Practices (PDF - 18KB)

                                                                                  Content current as of:
      12/04/2017FDA Transparency Initiative Overview
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop